AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$AUPH

Robertson Stephen P. sold $190K of AUPH

Robertson Stephen P. (Chief Legal Officer) sold 11,939 shares of Aurinia Pharmaceuticals Inc. (AUPH) at $15.95 ($0.19M total) on 2026-09-10.

Original reporting
SEC EDGAR · Robertson Stephen P.
Published Sep 11, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AUPH
Neutral
high confidence
Mentioned
$AUPH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AUPHNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market relevance.

02

Market read

Minor insider sale; unlikely to affect Aurinia's stock price.

03

What to watch

No additional corporate actions or news accompany the filing.

Relevance 4/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$AUPHNeutralHigh confidence
Context

Chief Legal Officer Stephen P. Robertson sold 11,939 shares for $190,427, reducing his stake to 588,848 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is modest relative to float and typical insider transactions; market likely to view as routine.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could signal insider concern, but size is too small to be meaningful.

Key entities

  • Company
    Aurinia Pharmaceuticals Inc.

    Biopharmaceutical company listed on NASDAQ under ticker AUPH.

  • Individual
    Stephen P. Robertson

    Chief Legal Officer of Aurinia Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AUPH insider trading history →

Related articles

$AUPHMedAI 8/10

Aurinia Skids on Results

Aurinia Pharmaceuticals reported Q3 and YTD 2026 revenue of $83.7M and $244.6M, up 14% and 19% YoY. LUPKYNIS sales rose 12% and 18% YoY for the same periods. License, collaboration, and royalty revenue increased 54% and 39% YoY. Net income before taxes grew 21% and 67% YoY.

baystreet.ca
$AUPHHigh

Aurinia Pharmaceuticals stock falls 3% on Q3 miss, soft guidance

Aurinia Pharmaceuticals (AUPH) reported Q3 earnings of $0.23 per share, missing estimates by $0.01, and revenue of $83.7M, slightly below expectations. Shares fell 3.43% premarket. The company raised 2026 revenue guidance to $325M-$330M, below analyst consensus. LUPKYNIS sales grew 12% YoY to $79.4M. The company also initiated a Phase 4 study for lupus nephritis treatments.

investing.com
$AUPHHigh

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (AUPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress EDMONTON, Alberta – October 30, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial resul

SEC EDGAR 8-K